Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: A retrospective preliminary study

American Journal of Clinical Dermatology

Volumn 9, Issue 5, 2008, Pages 323-331

  Mignogna, Michele Davide ^a   Leuci, Stefania ^a   Fedele, Stefano ^a,b   Ruoppo, Elvira ^a   Adamo, Daniela ^a   Russo, Giuseppina ^c   Pagliuca, Raffaella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Immunoglobulins, therapeutic use; Pemphigus, treatment

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BECLOMETASONE; BETAMETHASONE; BUDESONIDE; CHLORHEXIDINE; CHLORPHENIRAMINE; CLOBETASOL; CYCLOPHOSPHAMIDE; DAPSONE; HEPARIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PARACETAMOL; PREDNISONE; TRIAMCINOLONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CHILL; CHRONIC DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; FLUSHING; FOLLOW UP; HEADACHE; HEALTH CARE COST; HUMAN; LENGTH OF STAY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; ORAL MUCOSAL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DEFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 50049134925     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809050-00007     Document Type: Article

References (35)

1. Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am 1998; 82: 1239-83
2. Korman N. Pemphigus. J Am Acad Dermatol 1988; 18: 1219-38
3. Toth GG, Jonkman MF. Therapy of pemphigus vulgaris. Clin Dermatol 2001; 19: 761-7
4. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422-7
5. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus, an update. Arch Dermatol 1996; 132: 203-12
6. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358-63
7. Ahmed RA. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treat-ment. J Am Acad Dermatol 2001; 45: 679-90
8. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138: 1158-62
9. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immunoglobulins. N Engl J Med 2006; 355 (17): 1772-9
10. Ahmed RA. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006; 6: 557-78
11. Ahmed RA. Future horizons. Int Immunopharmacol 2006; 6: 607-9
12. Siegel J. Safety considerations in IVIg utilization. Int Immunopharmacol 2006; 6: 523-7
13. Yu Z, Lennon VA. Mechanism of intravenous immunoglobulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8
14. Bystryn JC, Rudolph JL, Perelman RO. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005; 125: 1093-8
15. Bhol KC, Desai A, Kumari S, et al. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 2001; 100: 172-80
16. Bayari J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006; 6: 528-34
17. Arredondo J, Chernyavsky AI, Karaouni A, et al. Novel mechanism of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005; 167: 1531-44
18. Lin N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115: 3440-50
19. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003; 13: 377-81
20. Ahmed AR, Dahl MV, for the Consensus Development Group. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051-9
21. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460-80
22. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-42
23. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-8
24. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thrombo-embolic complications. Lupus 2005; 14: 802-8
25. Shoham-Kessary H, Gershon H. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration. Vox Sang 1999; 77: 33-9
26. Kessary-Shoham H, Levy Y, Shoenfeld Y, et al. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999; 13: 129-35
27. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005; 366: 61-73
28. Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol 2001; 45: 775-83
29. Engineer L, Bhol KC, Ahmed RA. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049-57
30. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46: 741-53
31. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11
32. Segura S, Iranzo P, Martinez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56 (6): 960-7
33. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80 (1): 41-7
34. Gelfand EW. Differences between IVIg products: impact on clinical outcome. Int Immunopharmacol 2006; 6: 592-9
35. Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006; 6: 600-6